Cargando…

Overexpression of SYF2 promotes cell proliferation and correlates with poor prognosis in human breast cancer

SYF2, a known cell cycle regulator, is reported to be involved in cell cycle arrest by interacting with cyclin-D-type binding protein 1. In the present study, we investigated the role of SYF2 in human breast cancer (BC) progression. SYF2 was highly upregulated in BC tissues and cell lines, as per We...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Feng, Cai, Feng-Feng, Cai, Lu, Lin, Xiao-Yan, Zhang, Wei, Wang, Qin-Qin, Zhao, Yu-Jie, Ni, Qi-Chao, Wang, Hua, He, Zhi-Xian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5687618/
https://www.ncbi.nlm.nih.gov/pubmed/29179448
http://dx.doi.org/10.18632/oncotarget.18188
_version_ 1783278992481058816
author Shi, Feng
Cai, Feng-Feng
Cai, Lu
Lin, Xiao-Yan
Zhang, Wei
Wang, Qin-Qin
Zhao, Yu-Jie
Ni, Qi-Chao
Wang, Hua
He, Zhi-Xian
author_facet Shi, Feng
Cai, Feng-Feng
Cai, Lu
Lin, Xiao-Yan
Zhang, Wei
Wang, Qin-Qin
Zhao, Yu-Jie
Ni, Qi-Chao
Wang, Hua
He, Zhi-Xian
author_sort Shi, Feng
collection PubMed
description SYF2, a known cell cycle regulator, is reported to be involved in cell cycle arrest by interacting with cyclin-D-type binding protein 1. In the present study, we investigated the role of SYF2 in human breast cancer (BC) progression. SYF2 was highly upregulated in BC tissues and cell lines, as per Western blot and immunohistochemistry analysis. The SYF2 expression level had a significant correlation with the tumor grade and Ki-67 expression. In vitro starvation-refeeding experiment and SYF2-siRNA transfection assay demonstrated that SYF2 could promote proliferation of BC cells, while SYF2 knockdown resulted in cells cycle arrest at G1/S phase, reducing the cell growth rate of BC cells. These results indicated that SYF2 promotes human BC progression by accelerating the BC cells’ proliferation. SYF2 could be a novel therapeutic target in human BC therapies.
format Online
Article
Text
id pubmed-5687618
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-56876182017-11-20 Overexpression of SYF2 promotes cell proliferation and correlates with poor prognosis in human breast cancer Shi, Feng Cai, Feng-Feng Cai, Lu Lin, Xiao-Yan Zhang, Wei Wang, Qin-Qin Zhao, Yu-Jie Ni, Qi-Chao Wang, Hua He, Zhi-Xian Oncotarget Research Paper SYF2, a known cell cycle regulator, is reported to be involved in cell cycle arrest by interacting with cyclin-D-type binding protein 1. In the present study, we investigated the role of SYF2 in human breast cancer (BC) progression. SYF2 was highly upregulated in BC tissues and cell lines, as per Western blot and immunohistochemistry analysis. The SYF2 expression level had a significant correlation with the tumor grade and Ki-67 expression. In vitro starvation-refeeding experiment and SYF2-siRNA transfection assay demonstrated that SYF2 could promote proliferation of BC cells, while SYF2 knockdown resulted in cells cycle arrest at G1/S phase, reducing the cell growth rate of BC cells. These results indicated that SYF2 promotes human BC progression by accelerating the BC cells’ proliferation. SYF2 could be a novel therapeutic target in human BC therapies. Impact Journals LLC 2017-05-23 /pmc/articles/PMC5687618/ /pubmed/29179448 http://dx.doi.org/10.18632/oncotarget.18188 Text en Copyright: © 2017 Shi et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Shi, Feng
Cai, Feng-Feng
Cai, Lu
Lin, Xiao-Yan
Zhang, Wei
Wang, Qin-Qin
Zhao, Yu-Jie
Ni, Qi-Chao
Wang, Hua
He, Zhi-Xian
Overexpression of SYF2 promotes cell proliferation and correlates with poor prognosis in human breast cancer
title Overexpression of SYF2 promotes cell proliferation and correlates with poor prognosis in human breast cancer
title_full Overexpression of SYF2 promotes cell proliferation and correlates with poor prognosis in human breast cancer
title_fullStr Overexpression of SYF2 promotes cell proliferation and correlates with poor prognosis in human breast cancer
title_full_unstemmed Overexpression of SYF2 promotes cell proliferation and correlates with poor prognosis in human breast cancer
title_short Overexpression of SYF2 promotes cell proliferation and correlates with poor prognosis in human breast cancer
title_sort overexpression of syf2 promotes cell proliferation and correlates with poor prognosis in human breast cancer
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5687618/
https://www.ncbi.nlm.nih.gov/pubmed/29179448
http://dx.doi.org/10.18632/oncotarget.18188
work_keys_str_mv AT shifeng overexpressionofsyf2promotescellproliferationandcorrelateswithpoorprognosisinhumanbreastcancer
AT caifengfeng overexpressionofsyf2promotescellproliferationandcorrelateswithpoorprognosisinhumanbreastcancer
AT cailu overexpressionofsyf2promotescellproliferationandcorrelateswithpoorprognosisinhumanbreastcancer
AT linxiaoyan overexpressionofsyf2promotescellproliferationandcorrelateswithpoorprognosisinhumanbreastcancer
AT zhangwei overexpressionofsyf2promotescellproliferationandcorrelateswithpoorprognosisinhumanbreastcancer
AT wangqinqin overexpressionofsyf2promotescellproliferationandcorrelateswithpoorprognosisinhumanbreastcancer
AT zhaoyujie overexpressionofsyf2promotescellproliferationandcorrelateswithpoorprognosisinhumanbreastcancer
AT niqichao overexpressionofsyf2promotescellproliferationandcorrelateswithpoorprognosisinhumanbreastcancer
AT wanghua overexpressionofsyf2promotescellproliferationandcorrelateswithpoorprognosisinhumanbreastcancer
AT hezhixian overexpressionofsyf2promotescellproliferationandcorrelateswithpoorprognosisinhumanbreastcancer